JP2019522032A - 前立腺癌の治療方法 - Google Patents

前立腺癌の治療方法 Download PDF

Info

Publication number
JP2019522032A
JP2019522032A JP2019504790A JP2019504790A JP2019522032A JP 2019522032 A JP2019522032 A JP 2019522032A JP 2019504790 A JP2019504790 A JP 2019504790A JP 2019504790 A JP2019504790 A JP 2019504790A JP 2019522032 A JP2019522032 A JP 2019522032A
Authority
JP
Japan
Prior art keywords
prostate cancer
nilaparib
treatment
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019504790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522032A5 (de
Inventor
ゴッタルディス，マルコ
ホーキンス，レベッカ
スナイダー，リンダ
エイチ． ヤマダ，ダグラス
エイチ． ヤマダ，ダグラス
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2019522032A publication Critical patent/JP2019522032A/ja
Publication of JP2019522032A5 publication Critical patent/JP2019522032A5/ja
Priority to JP2022084991A priority Critical patent/JP7569353B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019504790A 2016-07-29 2017-07-28 前立腺癌の治療方法 Withdrawn JP2019522032A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022084991A JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662368466P 2016-07-29 2016-07-29
US62/368,466 2016-07-29
US201662369239P 2016-08-01 2016-08-01
US62/369,239 2016-08-01
PCT/US2017/044413 WO2018023017A1 (en) 2016-07-29 2017-07-28 Methods of treating prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084991A Division JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法

Publications (2)

Publication Number Publication Date
JP2019522032A true JP2019522032A (ja) 2019-08-08
JP2019522032A5 JP2019522032A5 (de) 2020-09-03

Family

ID=59649991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019504790A Withdrawn JP2019522032A (ja) 2016-07-29 2017-07-28 前立腺癌の治療方法
JP2022084991A Active JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022084991A Active JP7569353B2 (ja) 2016-07-29 2022-05-25 前立腺癌の治療方法

Country Status (20)

Country Link
US (8) US20180028521A1 (de)
EP (1) EP3490560A1 (de)
JP (2) JP2019522032A (de)
KR (2) KR20190033599A (de)
CN (1) CN109640991A (de)
AU (2) AU2017302660B2 (de)
BR (1) BR112019001398A2 (de)
CA (1) CA3031705A1 (de)
CO (1) CO2019000753A2 (de)
DO (1) DOP2019000019A (de)
IL (1) IL264443A (de)
MA (1) MA45780A (de)
MX (2) MX2019001224A (de)
NI (1) NI201900009A (de)
PE (1) PE20190403A1 (de)
PH (1) PH12019500135A1 (de)
SG (1) SG11201900361RA (de)
SV (1) SV2019005822A (de)
UA (1) UA124972C2 (de)
WO (1) WO2018023017A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA3031705A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
WO2019133697A1 (en) * 2017-12-27 2019-07-04 Tesaro, Inc. Methods of treating cancer
CA3100513A1 (en) * 2018-05-16 2019-11-21 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20210340122A1 (en) * 2018-09-05 2021-11-04 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
MX2024000949A (es) * 2021-07-19 2024-02-08 Janssen Pharmaceutica Nv Tratamiento de cancer de prostata metastasico resistente a la castracion con niraparib.

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
AU603340B2 (en) 1985-08-02 1990-11-15 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Novel vitamin d analogues
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
DE4021433A1 (de) 1990-07-04 1992-01-09 Schering Ag Antiandrogene mit steroid(3,2-c)pyrazol-struktur
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
JP2742331B2 (ja) 1992-03-31 1998-04-22 ブリテイツシユ・テクノロジー・グループ・リミテツド 癌治療に有用な１７位置換ステロイド
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB2282377B (en) 1993-09-30 1997-09-03 British Tech Group Synthesis of 17-(3-pyridyl) steroids
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
JP4172726B2 (ja) 1996-05-22 2008-10-29 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
AU762481C (en) 1998-03-27 2004-08-19 Oregon Health Sciences University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
WO2000038715A2 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
DK1276482T3 (da) 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
JPWO2001081364A1 (ja) 2000-04-24 2004-01-08 協和醗酵工業株式会社 エストラ−１，３，５（１０）−トリエン誘導体
EP1676577A1 (de) 2000-05-15 2006-07-05 Celgene Corporation Pharmazeutische Zusammensetzungen zur Behandlung von Krebs welche Thalidomid und Topoisomerase Inhibitoren enthalten
MXPA02011218A (es) 2000-05-15 2004-08-19 Celgene Corp Composiciones y metodos para el tratamiento de cancer.
MXPA02012198A (es) 2000-06-09 2004-08-19 Teni Boulikas Encapsulacion de polinucleotidos y drogas en liposomas objetivos.
AU2000260772A1 (en) 2000-07-05 2002-01-14 Bryan Muehlberger Systems and methods of facilitating electronic payment transactions
AU2687702A (en) 2000-10-17 2002-04-29 Merck & Co Inc Orally active salts with tyrosine kinase activity
US6750213B2 (en) 2000-10-19 2004-06-15 Merck & Co., Inc. Estrogen receptor modulators
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
CA2443938C (en) 2001-04-18 2010-06-22 R. Richard Goehring Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
CA2444489C (en) 2001-04-18 2010-06-22 Euro-Celtique, S.A. Benzimidazolone compounds
SI1598339T1 (sl) 2001-04-18 2009-12-31 Euro Celtique Sa Derivati 1-(4-amino.cikloheksil)-1,3-dihidro-2h-benzimidazol-2-ona in sorodne spojine kot nociceptinski analogi in ORL1 ligandi za zdravljenje bolečine
CN1516584A (zh) 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
US6838584B2 (en) 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US6740641B2 (en) 2001-07-27 2004-05-25 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain
AU2002323406A1 (en) 2001-08-30 2003-03-18 Merck And Co., Inc. Tyrosine kinase inhibitors
CN1551878B (zh) 2001-09-06 2011-08-10 先灵公司 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂
AU2002361577A1 (en) 2001-10-30 2003-05-12 Merck And Co., Inc. Tyrosine kinase inhibitors
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
DK1472225T3 (da) 2002-02-01 2010-08-09 Euro Celtique Sa 2-Piperazinpyridiner, som er anvendelige til behandling af smerte
EP1336602A1 (de) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrat-Prodrugs zur Freisetzung von Stickstoffmonoxid in kontrollierter und selektiver Weise sowie deren Verwendung zur Prävention und Behandlung inflammatorischer, ischämischer und proliferativer Erkrankungen
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US20050159361A1 (en) 2002-03-11 2005-07-21 Takahito Hara Remedies for sex hormone-dependent disease
US7273869B2 (en) 2002-04-08 2007-09-25 Merck & Co., Inc. Inhibitors of Akt activity
EP1927858B1 (de) 2002-04-29 2013-01-09 Euro-Celtique S.A. Konformativ eingeschränkte Peptide zur Bindung des ORL-1-Rezeptors
EP1503757B1 (de) 2002-05-02 2007-12-19 Merck & Co., Inc. Tyrosinkinase-hemmer
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003247829A1 (en) 2002-06-28 2004-01-19 Euro-Celtique, S.A. Therapeutic piperazine derivatives useful for treating pain
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
EP1534336A4 (de) 2002-08-15 2005-12-14 Human Genome Sciences Inc Antikörper, die immunospezifisch an trail-rezeptoren binden
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
SI1556058T1 (sl) 2002-10-23 2008-02-29 Pantarhei Bioscience Bv Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka
JP2006507302A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド キナーゼ阻害剤
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
MXPA05006485A (es) 2002-12-17 2005-08-26 Schering Corp Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgeno.
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20050054620A1 (en) 2003-01-13 2005-03-10 Koeffler H. Phillip Paricalcitol as a chemotherapeutic agent
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
EP1633316A4 (de) 2003-05-06 2008-04-02 Human Genome Sciences Inc Antikörper, die immunospezifisch an trail-rezeptoren binden
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
EP1867644B1 (de) 2003-07-24 2009-05-20 Euro-Celtique S.A. Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
JP4521777B2 (ja) 2003-07-24 2010-08-11 ユーロ−セルティーク エス．エイ． 疼痛治療または予防に有用な４−ヘテロアリール−テトラヒドロピペリジル化合物
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
JP5148110B2 (ja) 2003-08-01 2013-02-20 ユーロ−セルティーク エス．エイ． 疼痛の治療に有用な治療薬
CA2535366A1 (en) 2003-08-27 2005-03-10 Merck Frosst Canada & Co. Cathepsin inhibitors
EP1664041B1 (de) 2003-09-22 2008-07-02 Euro-Celtique S.A. Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE602004017481D1 (de) 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
EP1673092B1 (de) 2003-10-17 2007-08-15 4 Aza Ip Nv Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie
WO2005107801A2 (en) 2004-04-29 2005-11-17 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies
US20060003950A1 (en) 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20060030608A1 (en) 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
CA2579732C (en) 2004-09-10 2014-08-12 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
EP1674479A1 (de) 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulierung von Fc-gamma-Rezeptoren zur Optimierung einer Immunotherapie
WO2006081152A2 (en) 2005-01-24 2006-08-03 Merck & Co., Inc. Estrogen receptor modulators
WO2006116716A2 (en) 2005-04-27 2006-11-02 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
JP2008539238A (ja) 2005-04-28 2008-11-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 治療用二機能性化合物
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
WO2007014327A2 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
US20100016409A1 (en) 2006-06-02 2010-01-21 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Rna Nanoparticles and Nanotubes
KR20090042779A (ko) 2006-06-30 2009-04-30 쉐링 코포레이션 Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
WO2008005266A2 (en) 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
PL2478907T3 (pl) 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2008127290A2 (en) 2006-10-12 2008-10-23 The Johns Hopkins University Alginate and alginate lyase compositions and methods of use
WO2008062466A2 (en) 2006-10-13 2008-05-29 Reliance Life Sciences Pvt. Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
KR20090110913A (ko) 2007-02-15 2009-10-23 노파르티스 아게 Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물
EP2139522A2 (de) 2007-03-06 2010-01-06 Colby Pharmaceutical Company Auf mitochondrien gerichtete kationische antioxidationsverbindungen zur prävention, therapie oder behandlung von hyperproliferativen erkrankungen, neoplasien und karzinomen
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
AU2009203598B2 (en) 2008-01-08 2013-09-26 Merck Sharp & Dohme Llc Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3- yl]phenyl} -2H-indazole-7-carboxamide
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
CA2723590C (en) 2008-05-07 2017-06-27 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2012009475A1 (en) 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
WO2014089324A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Substituted cyclic compounds and methods of use
US9797771B2 (en) 2013-03-21 2017-10-24 Isp Investments Inc. Diacetylene film sensitized with photoinitiator and applications of the film
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2015164586A1 (en) 2014-04-23 2015-10-29 The Brigham And Women's Hospital, Inc. Targeting parp1 for treatment of tsc and cancers
US20150344968A1 (en) 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
WO2017023694A1 (en) 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
CA3031705A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
EP3534910A4 (de) 2016-10-04 2020-11-25 Pop Test Oncology LLC Therapeutika und verfahren
US11702443B2 (en) 2016-10-04 2023-07-18 Pop Test Oncology Llc Therapeutic agents and methods
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
CA3077678A1 (en) 2017-10-11 2019-04-18 Janssen Oncology, Inc. Methods of treating prostate cancer by administering abiraterone acetate plus prednisone with androgen deprivation therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUGS OF THE FUTURE, vol. 38, no. 10, JPN6021015328, 2013, pages 679 - 685, ISSN: 0004493217 *
LANCET ONCOL, vol. 14, JPN6021015330, 2013, pages 882 - 892, ISSN: 0004493218 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 373, no. 18, JPN6021015333, 2015, pages 1697 - 1708, ISSN: 0004493219 *

Also Published As

Publication number Publication date
US20230098047A1 (en) 2023-03-30
NI201900009A (es) 2019-05-10
BR112019001398A2 (pt) 2019-05-07
US11992486B2 (en) 2024-05-28
UA124972C2 (uk) 2021-12-22
US20220071979A1 (en) 2022-03-10
US20230149380A1 (en) 2023-05-18
CA3031705A1 (en) 2018-02-01
WO2018023017A1 (en) 2018-02-01
US11986468B2 (en) 2024-05-21
JP2022122920A (ja) 2022-08-23
MA45780A (fr) 2019-06-05
IL264443A (en) 2019-02-28
JP7569353B2 (ja) 2024-10-17
AU2017302660B2 (en) 2023-04-20
MX2023011187A (es) 2023-10-02
KR20190033599A (ko) 2019-03-29
CN109640991A (zh) 2019-04-16
MX2019001224A (es) 2019-06-03
DOP2019000019A (es) 2019-09-30
EP3490560A1 (de) 2019-06-05
US20180028521A1 (en) 2018-02-01
US11986470B2 (en) 2024-05-21
SV2019005822A (es) 2019-03-28
PH12019500135A1 (en) 2019-10-28
CO2019000753A2 (es) 2019-02-08
PE20190403A1 (es) 2019-03-13
US20240000766A1 (en) 2024-01-04
US11207311B2 (en) 2021-12-28
US20220071980A1 (en) 2022-03-10
AU2017302660A1 (en) 2019-01-24
AU2023202813A1 (en) 2023-05-25
US20190022079A1 (en) 2019-01-24
KR20240115925A (ko) 2024-07-26
US20230078160A1 (en) 2023-03-16
US11986469B2 (en) 2024-05-21
SG11201900361RA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
JP7569353B2 (ja) 前立腺癌の治療方法
JP2024023344A (ja) 前立腺癌の併用療法
JP2022508183A (ja) 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
JP2013545759A (ja) 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択
US10668039B2 (en) Methods for treatment of adenoid cystic carcinoma
EP4103286A1 (de) Verfahren zur behandlung von bauchspeicheldrüsenkrebs
JP2024150638A (ja) 前立腺癌の治療方法
EA040279B1 (ru) Способы лечения рака предстательной железы
KR102544211B1 (ko) 대사성 글루타메이트 수용체 5가 활성화된 자연 살해 세포 및 이의 용도
KR20240142398A (ko) 암을 치료하는데 사용하기 위한 치환된 피리미딘-4(3h)-온
JP2024538726A (ja) 癌の処置に使用するための置換ピリミジン－４（３ｈ）－オン
JP2024506684A (ja) Ｐａｒｐ７阻害物質の投与レジメン
JP2023059508A (ja) 悪性中皮腫の治療薬
KR20240037954A (ko) 니라파립을 이용한 전이성 거세-저항성 전립선암의 치료
WO2023205795A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220525

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20220607

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240219